Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Adverse Drug Reactions in Paediatric In-Patients in a South African Tertiary Hospital.

Makiwane M, Decloedt E, Chirehwa M, Rosenkranz B, Kruger M.

J Trop Pediatr. 2019 Aug 1;65(4):389-396. doi: 10.1093/tropej/fmy067.

PMID:
30544245
2.

Off-label Use in Ambulatory Paediatric Clinics in a Central South African Hospital.

Kruger M, Makiwane MM, Ramoroka S, van Elsland SL, Lawrence K, Rosenkranz B.

J Trop Pediatr. 2019 Aug 1;65(4):380-388. doi: 10.1093/tropej/fmy065.

PMID:
30476332
3.

B-cell and T-cell activation in South African HIV-1-positive non-Hodgkin's lymphoma patients.

Flepisi BT, Bouic P, Sissolak G, Rosenkranz B.

South Afr J HIV Med. 2018 Nov 7;19(1):809. doi: 10.4102/sajhivmed.v19i1.809. eCollection 2018.

4.

Lopinavir serum concentrations of critically ill infants: a pharmacokinetic investigation in South Africa.

Schultheiß M, Kling S, Lenker U, von Bibra M, Rosenkranz B, Klinker H.

Med Microbiol Immunol. 2018 Nov;207(5-6):339-343. doi: 10.1007/s00430-018-0550-5. Epub 2018 Jul 4.

PMID:
29974233
5.

Evaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin Concentrations.

Abulfathi AA, Chirehwa M, Rosenkranz B, Decloedt EH.

J Clin Pharmacol. 2018 Sep;58(9):1134-1139. doi: 10.1002/jcph.1254. Epub 2018 May 10.

PMID:
29746714
6.

Critical evaluation of causality assessment of herb-drug interactions in patients.

Awortwe C, Makiwane M, Reuter H, Muller C, Louw J, Rosenkranz B.

Br J Clin Pharmacol. 2018 Apr;84(4):679-693. doi: 10.1111/bcp.13490. Epub 2018 Jan 29. Review.

7.

Association between Health-Related Quality of Life and Medication Adherence in Pulmonary Tuberculosis in South Africa.

Kastien-Hilka T, Rosenkranz B, Schwenkglenks M, Bennett BM, Sinanovic E.

Front Pharmacol. 2017 Dec 18;8:919. doi: 10.3389/fphar.2017.00919. eCollection 2017.

8.

MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2.

Awortwe C, Kaehler M, Rosenkranz B, Cascorbi I, Bruckmueller H.

Xenobiotica. 2018 Oct;48(10):1050-1058. doi: 10.1080/00498254.2017.1390624. Epub 2017 Nov 2.

PMID:
28990842
9.

Health-related quality of life in South African patients with pulmonary tuberculosis.

Kastien-Hilka T, Rosenkranz B, Sinanovic E, Bennett B, Schwenkglenks M.

PLoS One. 2017 Apr 20;12(4):e0174605. doi: 10.1371/journal.pone.0174605. eCollection 2017.

11.

How to Evaluate Health-Related Quality of Life and Its Association with Medication Adherence in Pulmonary Tuberculosis - Designing a Prospective Observational Study in South Africa.

Kastien-Hilka T, Rosenkranz B, Bennett B, Sinanovic E, Schwenkglenks M.

Front Pharmacol. 2016 May 31;7:125. doi: 10.3389/fphar.2016.00125. eCollection 2016.

12.

Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis- a systematic review of global literature with focus on South Africa.

Kastien-Hilka T, Abulfathi A, Rosenkranz B, Bennett B, Schwenkglenks M, Sinanovic E.

Health Qual Life Outcomes. 2016 Mar 11;14:42. doi: 10.1186/s12955-016-0442-6. Review.

13.

In vivo monitoring of urea cycle activity with (13)C-acetate as a tracer of ureagenesis.

Opladen T, Lindner M, Das AM, Marquardt T, Khan A, Emre SH, Burton BK, Barshop BA, Böhm T, Meyburg J, Zangerl K, Mayorandan S, Burgard P, Dürr UH, Rosenkranz B, Rennecke J, Derbinski J, Yudkoff M, Hoffmann GF.

Mol Genet Metab. 2016 Jan;117(1):19-26. doi: 10.1016/j.ymgme.2015.11.007. Epub 2015 Nov 14.

PMID:
26597322
14.

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR.

Antimicrob Agents Chemother. 2015 Jul;59(7):4129-38. doi: 10.1128/AAC.04049-14. Epub 2015 May 11.

15.

Education and training for medicines development, regulation, and clinical research in emerging countries.

Kerpel-Fronius S, Rosenkranz B, Allen E, Bass R, Mainard JD, Dodoo A, Dubois DJ, Hela M, Kern S, Massud J, Silva H, Whitty J.

Front Pharmacol. 2015 Apr 14;6:80. doi: 10.3389/fphar.2015.00080. eCollection 2015.

16.

Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Decloedt EH, Rosenkranz B, Maartens G, Joska J.

Clin Pharmacokinet. 2015 Jun;54(6):581-98. doi: 10.1007/s40262-015-0257-3.

PMID:
25777740
17.

Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Sy SK, Malmberg R, Matsushima A, Asin-Prieto E, Rosenkranz B, Cotton MF, Derendorf H, Innes S.

Int J Antimicrob Agents. 2015 Apr;45(4):413-9. doi: 10.1016/j.ijantimicag.2014.12.016. Epub 2015 Jan 19.

18.

In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities.

Awortwe C, Manda VK, Avonto C, Khan SI, Khan IA, Walker LA, Bouic PJ, Rosenkranz B.

Drug Metab Lett. 2015;9(1):48-62.

19.

The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction.

Fasinu PS, Bouic PJ, Rosenkranz B.

Afr J Tradit Complement Altern Med. 2014 Jun 4;11(4):54-61. eCollection 2014.

20.

Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway.

Awortwe C, Manda VK, Avonto C, Khan SI, Khan IA, Walker LA, Bouic PJ, Rosenkranz B.

Xenobiotica. 2015 Mar;45(3):218-29. doi: 10.3109/00498254.2014.973930. Epub 2014 Nov 7.

21.

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR.

Antimicrob Agents Chemother. 2014 Oct;58(10):6242-50. doi: 10.1128/AAC.03073-14. Epub 2014 Aug 11.

22.

Biomarkers of HIV-associated Cancer.

Flepisi BT, Bouic P, Sissolak G, Rosenkranz B.

Biomark Cancer. 2014 Jul 3;6:11-20. doi: 10.4137/BIC.S15056. eCollection 2014. Review.

23.

Drug-drug interactions in HIV positive cancer patients.

Flepisi BT, Bouic P, Sissolak G, Rosenkranz B.

Biomed Pharmacother. 2014 Jun;68(5):665-77. doi: 10.1016/j.biopha.2014.04.010. Epub 2014 Apr 28. Review.

PMID:
24863536
24.

Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges.

Awortwe C, Fasinu PS, Rosenkranz B.

J Pharm Pharm Sci. 2014;17(1):1-19. Review.

25.
26.

Editorial: diagnosis and management of malaria: an updated report on a deadly disease of global impact.

Rosenkranz B, Nachega JB.

Infect Disord Drug Targets. 2013 Aug;13(4):215-6. No abstract available.

PMID:
24410675
27.

Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.

Sy SK, Innes S, Derendorf H, Cotton MF, Rosenkranz B.

Antimicrob Agents Chemother. 2014;58(2):1084-91. doi: 10.1128/AAC.01717-13. Epub 2013 Dec 2.

28.

Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?

von Bibra M, Rosenkranz B, Pretorius E, Rabie H, Edson C, Lenker U, Cotton M, Klinker H.

Paediatr Int Child Health. 2014 May;34(2):138-41. doi: 10.1179/2046905513Y.0000000090. Epub 2013 Dec 6.

PMID:
24225343
29.

The potential of Hypoxis hemerocallidea for herb-drug interaction.

Fasinu PS, Gutmann H, Schiller H, Bouic PJ, Rosenkranz B.

Pharm Biol. 2013 Dec;51(12):1499-507. doi: 10.3109/13880209.2013.796393. Epub 2013 Jul 11.

PMID:
23844611
30.

Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area.

Njovane XW, Fasinu PS, Rosenkranz B.

Cardiovasc J Afr. 2013 Mar;24(2):19-23.

31.

The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care.

Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, Seifart HI, Bolliger CT.

S Afr Med J. 2013 Apr 5;103(6):394-8. doi: 10.7196/samj.6344.

PMID:
23725959
32.

Clinical pharmacology becomes a specialty in South Africa.

Walubo A, Barnes KI, Kwizera E, Greeff O, Rosenkranz B, Maartens G.

S Afr Med J. 2013 Jan 9;103(3):150-1. doi: 10.7196/samj.6639.

PMID:
23472687
33.
34.

The potential of Sutherlandia frutescens for herb-drug interaction.

Fasinu PS, Gutmann H, Schiller H, James AD, Bouic PJ, Rosenkranz B.

Drug Metab Dispos. 2013 Feb;41(2):488-97. doi: 10.1124/dmd.112.049593. Epub 2012 Dec 3.

PMID:
23209194
35.

Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.

Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR.

J Trop Pediatr. 2013 Apr;59(2):90-4. doi: 10.1093/tropej/fms053. Epub 2012 Nov 21.

PMID:
23174991
36.

An overview of the evidence and mechanisms of herb-drug interactions.

Fasinu PS, Bouic PJ, Rosenkranz B.

Front Pharmacol. 2012 Apr 30;3:69. doi: 10.3389/fphar.2012.00069. eCollection 2012.

37.

Liver-based in vitro technologies for drug biotransformation studies - a review.

Fasinu P, Bouic PJ, Rosenkranz B.

Curr Drug Metab. 2012 Feb;13(2):215-24. Review.

PMID:
22300020
38.

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

Nachega JB, Rosenkranz B, Pham PA.

Patient Prefer Adherence. 2011;5:645-51. doi: 10.2147/PPA.S27558. Epub 2011 Dec 28.

39.

Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.

Innes S, Norman J, Smith P, Smuts M, Capparelli E, Rosenkranz B, Cotton M.

Antivir Ther. 2011;16(7):1131-4. doi: 10.3851/IMP1876.

40.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

41.

Pharmacokinetics of ethionamide in children.

Thee S, Seifart HI, Rosenkranz B, Hesseling AC, Magdorf K, Donald PR, Schaaf HS.

Antimicrob Agents Chemother. 2011 Oct;55(10):4594-600. doi: 10.1128/AAC.00379-11. Epub 2011 Jul 25.

42.

The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection.

Pretorius E, Klinker H, Rosenkranz B.

Ther Drug Monit. 2011 Jun;33(3):265-74. doi: 10.1097/FTD.0b013e31821b42d1. Review.

PMID:
21566505
43.

Targeting tuberculosis and HIV/AIDS: a global progress report of a deadly partnership.

Nachega JB, Rosenkranz B.

Infect Disord Drug Targets. 2011 Apr;11(2):96-7. No abstract available.

PMID:
21406055
44.

Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives.

Nachega JB, Rosenkranz B, Simon G, Chaisson RE, Diacon A, Taljaard J.

Infect Disord Drug Targets. 2011 Apr;11(2):134-43. Review.

PMID:
21406051
45.

Population pharmacokinetic analysis of the active product of dipyrone.

Levy M, Muszkat M, Rich B, Rosenkranz B, Schlattmann P.

Int J Clin Pharmacol Ther. 2010 Dec;48(12):791-7.

PMID:
21084034
46.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT.

N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.

48.

Results of an international ring test with the dung fly Musca autumnalis in support of a new OECD test guideline.

Römbke J, Barrett K, Blanckenhorn WU, Hargreaves T, Kadiri N, Knäbe S, Lehmhus J, Lumaret JP, Rosenkranz B, Scheffczyk A, Sekine T.

Sci Total Environ. 2010 Sep 1;408(19):4102-6. doi: 10.1016/j.scitotenv.2010.05.027. Epub 2010 Jun 9.

PMID:
20542534
49.

Lethal and sublethal toxic effects of a test chemical (ivermectin) on the yellow dung fly (Scathophaga stercoraria) based on a standardized international ring test.

Römbke J, Floate KD, Jochmann R, Schäfer MA, Puniamoorthy N, Knäbe S, Lehmhus J, Rosenkranz B, Scheffczyk A, Schmidt T, Sharples A, Blanckenhorn WU.

Environ Toxicol Chem. 2009 Oct;28(10):2117-24. doi: 10.1897/08-599.1.

PMID:
19432504
50.

Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.

Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G.

Gastroenterology. 2008 Sep;135(3):787-95. doi: 10.1053/j.gastro.2008.05.054. Epub 2008 May 28.

PMID:
18619971

Supplemental Content

Loading ...
Support Center